DATA ANOMALY IN THE PAPER ENTITLED "EFFECT OF DEXAMETHASONE IN HOSPITALIZED PATIENTS WITH COVID-19: PRELIMINARY REPORT", AUTHORED BY HORBY ET AL., AND PUBLISHED IN MEDRXIV [MEDRXIV (2020) DOI: 10.1101/2020.06.22.20137273]

The paper entitled "Effect of Dexamethasone in hospitalized patients with COVID-19: Preliminary report" by Horby et al. and published in medRxiv was highly anticipated because it offered the only slim hope that the lives of individuals infected with SARS-COV-2 could be saved. Before the paper appeared in medRxiv which cautioned that it had not been peer-reviewed, the authors had already orchestrated a big fanfare in front of the world's press (it is the new way of disseminating scientific data now-days!). Horby et al. concluded that "Prior to the completion of this trial, many COVID-19 treatment guidelines have stated that corticosteroids are either contraindicated or not recommended in COVID-19. These should now be updated as has already happened with the UK. Dexamethasone provides an effective treatment for the sickest patients with COVID and given its low cost, well understood profile and widespread availability, is one that can be used world-wide". Because of the Hydroxychloroquine fiasco and Remdesivir uncertainties, it is legitimate to investigate if the conclusions of Horby et al. are borne out by the presented data. Here, it is shown that there have been instances of Dishonest Scientific Reporting, violation of scientific ethics rule and data anomaly that must be resolved before one can pronounce whether Dexamethasone had any effects, one way or another on the mortality of SARS-COV-2 infected patients who were admitted into hospital care. Data anomaly in the paper of Horby et al. include: (i) In Horby et al., the mortality rate of patients who did not require oxygen and invasive mechanical ventilation was ~25% whereas in other countries, including France, China and the United States, the mortality rate of patients is ~16% for all patients admitted to hospital care in the absence of Dexamethasone treatment, (ii) In Horby et al., the mortality rate of all patients admitted to hospital care requiring oxygen was ~25% whereas in a comparable study in France, the mortality rate was ~9%, and (iii) In Horby et al., the mortality rate of patients who required oxygen and invasive mechanical ventilation was ~40% whereas in two comparable studies, the mortality rate was ~30%. It is not possible to explain the discrepancies of mortality rates reported in the study by Horby et al. and the other studies